ࡱ> z|wxy_"bjbj> bbXKKKKK____$,_v0ttttttt$>wyhtKtKKud]d]d]2KKtd]td]d]moTryW)M rtu0vrXzBZ"Xz4rrXzKsd]ttd]vXz? :"(/ ?@> ?@>2545==O A?@>I5=>W 70:C?V2;V 7 70AB>AC20==O< 5;5:B@>==>3> 0C:FV>=C 73V4=> 7V AB0BB5N 14 0:>=C #:@0W=8 @> ?C1;VG=V 70:C?V2;V 1. 0<>2=8:: 1.1. 09<5=C20==O:  "5@=>?V;LAL:0 :><C=0;L=0 <VAL:0 ;V:0@=O !2. 1.2. >4 2 48=><C 45@602=><C @5TAB@V N@848G=8E >AV1, DV78G=8E >AV1 - ?V4?@8T<FV2 B0 3@><04AL:8E D>@<C20=L: 05497361. 1.3. VAF57=0E>465==O: 2C;. .C?G8=AL:>3>,14 , <."5@=>?V;L, 46023. 1.4. 0B53>@VO 78<>2=8:0: .@848G=0 >A>10, O:0 70157?5GCT ?>B@518 45@6028 01> B5@8B>@V0;L=>W 3@><048. 1.5. >A04>20>A>10 70<>2=8:0, C?>2=>2065=0 74V9A=N20B8 72'O7>: 7 CG0A=8:0<8 (?@V728I5, V<'O, ?>-10BL:>2V, ?>A040, A;C61>20 04@5A0, B5;5D>=, 5;5:B@>==0 ?>HB0): VA5FL:0 #;O=0 >;>48<8@V2=0 D0EV25FL 7 ?C1;VG=8E 70:C?V25;L (C?>2=>2065=0 >A>10 70 >@30=V70FVN B0 74V9A=5==O A?@>I5=8E 70:C?V25;L), <."5@=>?V;L , 2C;. .C?G8=AL:>3>,14 , B5;./D0:A (0352) 268112, e-mail: tmkl2buh@gmail.com. 2. =D>@<0FVO ?@> ?@54<5B 70:C?V2;V : >4  021:2015:33690000-3 V:0@AL:V 70A>18 @V7=V (01>@0B>@=V @50:B828 ( 024:2019): 53307 "5AB 4;O :V;L:VA=>3> 287=0G5==O 3;N:>78 /Glucose HK Gen.3 (GLUC3), 53231 "5AB 4;O :V;L:VA=>3> 287=0G5==O 7030;L=>3> 2<VABC 1V;V@C1V=C, 250 B5ABV2/Bilirubin Total Gen.3, 53236 "5AB 4;O :V;L:VA=>3> 287=0G5==O ?@O<>3> 1V;V@C1V=C /Bilirubin-Direct (BIL-D2), 53989 "5AB 4;O 287=0G5==O 7030;L=>3> 2<VABC 1V;:C /TP2/Total Protein Gen.2 ,53590 "5AB 4;O :V;L:VA=>3> 287=0G5==O A5G>28=8/ 07>BC A5G>28=8 /(UREA), 53252 "5AB 4;O :V;L:VA=>3> 287=0G5==O :@50B8=8=C /Creatinine Jaff Gen.2 (700 tests), 53362 "5AB 4;O 287=0G5==O 7030;L=>3> E>;5AB5@8=C /CHOL HiCo Gen.2, cobas c, Int., 53462 "5AB 4;O :V;L:VA=>3> 287=0G5==O B@83;VF5@84V2 /Triglycerides (TRIGL), 53393 "5AB 4;O :V;L:VA=>3> 287=0G5==O E>;5AB5@8=C-), Gen.4 , 53412 "5AB 4;O 287=0G5==O )-E>;5AB5@8= 3 ?>:>;V==O (200 B5ABV2), 52925 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0;0=V=0<V=>B@0=AD5@078 (") /Alanine Aminotransferase acc. to IFCC (ALTL), 52955 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0A?0@B0B0<V=>B@0=AD5@078(!") /Aspartate Aminotransferase acc. to IFCC (ASTL), 52941 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0;LD0-0<V;078 /AMYL2/ alpha-Amylase EPS ver.2, 38502 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0;LD0-0<V;078 ?V4H;C=:>2>W 70;>78 /alpha-Amylase EPS Pancreatic (AMY-P), 52929 "5AB 4;O :V;L:VA=>3> 287=0G5==O ;C6=>W D>AD0B078, 400 B5ABV2 /Alkaline Phosphatase acc. to IFCC Gen.2 ALP2L, 53030 "5AB 4;O 287=0G5==O 30<<0-3;CB0<V;B@0=AD5@078 /GGT gamma-Glutamyltransferase ver.2 , 38512 "5AB 4;O :V;L:VA=>3> 287=0G5==O :0B0;VB8G=>W 0:B82=>ABV :@50B8=:V=078 MB-D@0:FVW CKMB2, 38512 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0:B82=>ABV :@50B8=:V=078, 200 B5ABV2, 53586 "5AB 4;O :V;L:VA=>3> 287=0G5==O A5G>2>W :8A;>B8 /UA2/Uric Acid ver.2 , 52875 "5AB 4;O :V;L:VA=>3> 287=0G5==O :0;LFVN (300 B5ABV2) /Calcium Gen.2 (300 tests), 54762 "5AB 4;O :V;L:VA=>3> 287=0G5==O 70;V70 /IRON2/Iron Gen.2 , 53908 "5AB 4;O :V;L:VA=>3> 287=0G5==O =5=0A8G5=>W 70;V7>72 O7CNG>W 740B=>ABV A8@>20B:8 :@>2V B0 ?;07<8 /UIBC Unsaturated Iron-Binding Capacity, 52883 "5AB 4;O :V;L:VA=>3> 287=0G5==O <03=VN, 25@ 2, 250 B5ABV2 / Magnesium Gen.2 250 tests), 52891 "5AB 4;O :V;L:VA=>3> 287=0G5==O =5>@30=VG=>3> D>AD0BC /PHOS2/Phosphate (Inorganic) ver.2, 53599 "5AB 4;O 287=0G5==O :>=F5=B@0FVW 0;L1C<V=C /ALB BCG Gen.2, cobas c, Int., 53719 "5AB 4;O :V;L:VA=>3> 287=0G5==O D5@8B8=C (250 B5ABV2) / Tina-quant Ferritin Gen.4 250 tests), 53994 "5AB 4;O :V;L:VA=>3> 287=0G5==O B@0=AD5@V=0 /TRSF Tina-quant Transferrin ver.2, 53316 "5AB 4;O :V;L:VA=>3> 287=0G5==O 35<>3;>1V=C /Tina-quant Hemoglobin A1c Gen.3, 47349 "5AB 4;O :V;L:VA=>3> 287=0G5==O ?@>4C:BV2 @>7?04C DV1@8=V2 (100 B5ABV2) /Tina-quant D-Dimer Gen.2 (100 tests), 53707 "5AB 4;O :V;L:VA=>3> 287=0G5==O !-@50:B82=>3> 1V;:0 (CRP), 4 35=., cobas c 311/501/502, Integra, 55113 "5AB 4;O :V;L:VA=>3> 287=0G5==O @52<0B>W4=>3> D0:B>@C /Rheumatoid Factors II (RF-II), 37756 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> AB@5?B>;V78=C  / ASLO" Tina-quant Antistreptolysin O, 47869 >=B@>;L Precicontrol Clinchem 1 (4x5<;) /Precicontrol Clinchem 1 (4x5ml), 47869 >=B@>;L Precicontrol Clinchem 2 (4x5<;) /Precicontrol Clinchem 2 (4x5ml), 52869 >7G8= 4;O @5D5@5=B=>3> 5;5:B@>40 /ISE Reference Electrolyte, 58237 ISE @>7102;N20G 4;O :V;L:VA=>3> 287=0G5==O =0B@VN, :0;VN, E;>@84C 2 A8@>20BFV, ?;07<V 01> A5GV, 52869 ISE AB0=40@B 2=CB@VH=V9 4;O :V;L:VA=>3> 287=0G5==O =0B@VN, :0;VN, E;>@84C 2 A8@>20BFV, ?;07<V 01> A5GV, 58236 @><82=89 @>7G8= NaOHD 4;O ?@>1 @5035=BC B0/01> @50:FV9=8E :0<5@ 2 A8AB5<0E Roche/Hitachi cobas c, 58237 >102:0 4;O 7=865==O ?>25@E=52>3> =0BO3C 2 @50:FV9=>W 20==V 0=0;V70B>@0 cobas c 311, 58236 @><82=89 @>7G8= Cell wash Solution I/NaOH-D, 61165 5<>;V7CNG89 @5035=B, 51 <; /H1CD2 Hemolyzing Reagent Gen.2, 54386 "5AB-A8AB5<0 4;O 287=0G5==O B8@5>B@>?=>3> 3>@<>=C 2 35=., 54413 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O =572'O70=>3> B8@>:A8=C, gen.III, 54417 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> B@89>4BV>=V=C /FT3 Gen.3, 54084 "5AB-A8AB5<0 4;O 287=0G5==O :0;LF8B>=V=C, 58728 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> B8@5>3;>1C;V=C, 25@ 4 /Anti-Tg Gen.4, 58729 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> B8@5>?5@>:A84078, 25@. 3 /Anti-TPO Gen.3, 54484 "5AB 4;O :V;L:VA=>3> 287=0G5==O 7030;L=>3> 25-3V4@>:A82VB0<V=C D /Vitamin D total, 54237 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O V=AC;V=C /Insulin, 54004 "5AB 4;O :V;L:VA=>3> 287=0G5==O A5@45G=>3> B@>?>=V=C ", 25@.2, 200 B5ABV2, 58731 "5AB 4;O :V;L:VA=>3> 287=0G5==O ?@>:0;LF8B>=V=C, 100 HB, 25@.2, 54665 01V@ @5035=BV2 Elecsys 4;O :V;L:VA=>3> 287=0G5==O :>=F5=B@0FVW 7030;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (Total PSA), 48323 01V@ @5035=BV2 Elecsys 4;O O:VA=>3> 287=0G5==O ?>25@E=52>3> 0=B835=C 2V@CAC 35?0B8BC B II (HBsAg II), 48366 01V@ @5035=BV2 Elecsys 4;O O:VA=>3> 287=0G5==O 0=B8BV; 4> 2V@CAC 35?0B8BC ! (Anti-HCV II), 53858 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O =B5@;59:V=0-6 (-6) /IL-6, 58236 !8AB5<=89 @>7G8= 4;O 35=5@0FVW 5;5:B@>EV<VG=8E A83=0;V2 2 V<C=>0=0;V70B>@0E Elecsys, cobas e, 59058 !8AB5<=89 @>7G8= 4;O G8AB:8 45B5:B>@=>3> 1;>:C, Elecsys, cobas e, 58236 >7G8= Elecsys Sys Wash, 61032 >2?0G>: (@50:FV9=0 ?@>1V@:0) 4;O 28:>@8AB0==O 2 A8AB5<0E cobas e 411/Elecsys 2010, 16822 0:V=5G=8: 4;O 28:>@8AB0==O 2 A8AB5<0E cobas e 411/Elecsys 2010, 61032 @>1V@:0 4;O 7@07:V2, 58237 >7G8==8: C=V25@A0;L=89 /Universal Diluent, 54670 01V@ @5035=BV2 Elecsys 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (free PSA), 38183 0;V1@C20;L=89 =01V@ 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (free PSA) 2.1. >=:@5B=0 =0720 ?@54<5B0 70:C?V2;V: 01>@0B>@=V @50:B828 ( 024:2019): 53307 "5AB 4;O :V;L:VA=>3> 287=0G5==O 3;N:>78 /Glucose HK Gen.3 (GLUC3), 53231 "5AB 4;O :V;L:VA=>3> 287=0G5==O 7030;L=>3> 2<VABC 1V;V@C1V=C, 250 B5ABV2/Bilirubin Total Gen.3, 53236 "5AB 4;O :V;L:VA=>3> 287=0G5==O ?@O<>3> 1V;V@C1V=C /Bilirubin-Direct (BIL-D2), 53989 "5AB 4;O 287=0G5==O 7030;L=>3> 2<VABC 1V;:C /TP2/Total Protein Gen.2 ,53590 "5AB 4;O :V;L:VA=>3> 287=0G5==O A5G>28=8/ 07>BC A5G>28=8 /(UREA), 53252 "5AB 4;O :V;L:VA=>3> 287=0G5==O :@50B8=8=C /Creatinine Jaff Gen.2 (700 tests), 53362 "5AB 4;O 287=0G5==O 7030;L=>3> E>;5AB5@8=C /CHOL HiCo Gen.2, cobas c, Int., 53462 "5AB 4;O :V;L:VA=>3> 287=0G5==O B@83;VF5@84V2 /Triglycerides (TRIGL), 53393 "5AB 4;O :V;L:VA=>3> 287=0G5==O E>;5AB5@8=C-), Gen.4 , 53412 "5AB 4;O 287=0G5==O )-E>;5AB5@8= 3 ?>:>;V==O (200 B5ABV2), 52925 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0;0=V=0<V=>B@0=AD5@078 (") /Alanine Aminotransferase acc. to IFCC (ALTL), 52955 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0A?0@B0B0<V=>B@0=AD5@078(!") /Aspartate Aminotransferase acc. to IFCC (ASTL), 52941 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0;LD0-0<V;078 /AMYL2/ alpha-Amylase EPS ver.2, 38502 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0;LD0-0<V;078 ?V4H;C=:>2>W 70;>78 /alpha-Amylase EPS Pancreatic (AMY-P), 52929 "5AB 4;O :V;L:VA=>3> 287=0G5==O ;C6=>W D>AD0B078, 400 B5ABV2 /Alkaline Phosphatase acc. to IFCC Gen.2 ALP2L, 53030 "5AB 4;O 287=0G5==O 30<<0-3;CB0<V;B@0=AD5@078 /GGT gamma-Glutamyltransferase ver.2 , 38512 "5AB 4;O :V;L:VA=>3> 287=0G5==O :0B0;VB8G=>W 0:B82=>ABV :@50B8=:V=078 MB-D@0:FVW CKMB2, 38512 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0:B82=>ABV :@50B8=:V=078, 200 B5ABV2, 53586 "5AB 4;O :V;L:VA=>3> 287=0G5==O A5G>2>W :8A;>B8 /UA2/Uric Acid ver.2 , 52875 "5AB 4;O :V;L:VA=>3> 287=0G5==O :0;LFVN (300 B5ABV2) /Calcium Gen.2 (300 tests), 54762 "5AB 4;O :V;L:VA=>3> 287=0G5==O 70;V70 /IRON2/Iron Gen.2 , 53908 "5AB 4;O :V;L:VA=>3> 287=0G5==O =5=0A8G5=>W 70;V7>72 O7CNG>W 740B=>ABV A8@>20B:8 :@>2V B0 ?;07<8 /UIBC Unsaturated Iron-Binding Capacity, 52883 "5AB 4;O :V;L:VA=>3> 287=0G5==O <03=VN, 25@ 2, 250 B5ABV2 / Magnesium Gen.2 250 tests), 52891 "5AB 4;O :V;L:VA=>3> 287=0G5==O =5>@30=VG=>3> D>AD0BC /PHOS2/Phosphate (Inorganic) ver.2, 53599 "5AB 4;O 287=0G5==O :>=F5=B@0FVW 0;L1C<V=C /ALB BCG Gen.2, cobas c, Int., 53719 "5AB 4;O :V;L:VA=>3> 287=0G5==O D5@8B8=C (250 B5ABV2) / Tina-quant Ferritin Gen.4 250 tests), 53994 "5AB 4;O :V;L:VA=>3> 287=0G5==O B@0=AD5@V=0 /TRSF Tina-quant Transferrin ver.2, 53316 "5AB 4;O :V;L:VA=>3> 287=0G5==O 35<>3;>1V=C /Tina-quant Hemoglobin A1c Gen.3, 47349 "5AB 4;O :V;L:VA=>3> 287=0G5==O ?@>4C:BV2 @>7?04C DV1@8=V2 (100 B5ABV2) /Tina-quant D-Dimer Gen.2 (100 tests), 53707 "5AB 4;O :V;L:VA=>3> 287=0G5==O !-@50:B82=>3> 1V;:0 (CRP), 4 35=., cobas c 311/501/502, Integra, 55113 "5AB 4;O :V;L:VA=>3> 287=0G5==O @52<0B>W4=>3> D0:B>@C /Rheumatoid Factors II (RF-II), 37756 "5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> AB@5?B>;V78=C  / ASLO" Tina-quant Antistreptolysin O, 47869 >=B@>;L Precicontrol Clinchem 1 (4x5<;) /Precicontrol Clinchem 1 (4x5ml), 47869 >=B@>;L Precicontrol Clinchem 2 (4x5<;) /Precicontrol Clinchem 2 (4x5ml), 52869 >7G8= 4;O @5D5@5=B=>3> 5;5:B@>40 /ISE Reference Electrolyte, 58237 ISE @>7102;N20G 4;O :V;L:VA=>3> 287=0G5==O =0B@VN, :0;VN, E;>@84C 2 A8@>20BFV, ?;07<V 01> A5GV, 52869 ISE AB0=40@B 2=CB@VH=V9 4;O :V;L:VA=>3> 287=0G5==O =0B@VN, :0;VN, E;>@84C 2 A8@>20BFV, ?;07<V 01> A5GV, 58236 @><82=89 @>7G8= NaOHD 4;O ?@>1 @5035=BC B0/01> @50:FV9=8E :0<5@ 2 A8AB5<0E Roche/Hitachi cobas c, 58237 >102:0 4;O 7=865==O ?>25@E=52>3> =0BO3C 2 @50:FV9=>W 20==V 0=0;V70B>@0 cobas c 311, 58236 @><82=89 @>7G8= Cell wash Solution I/NaOH-D, 61165 5<>;V7CNG89 @5035=B, 51 <; /H1CD2 Hemolyzing Reagent Gen.2, 54386 "5AB-A8AB5<0 4;O 287=0G5==O B8@5>B@>?=>3> 3>@<>=C 2 35=., 54413 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O =572'O70=>3> B8@>:A8=C, gen.III, 54417 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> B@89>4BV>=V=C /FT3 Gen.3, 54084 "5AB-A8AB5<0 4;O 287=0G5==O :0;LF8B>=V=C, 58728 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> B8@5>3;>1C;V=C, 25@ 4 /Anti-Tg Gen.4, 58729 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> B8@5>?5@>:A84078, 25@. 3 /Anti-TPO Gen.3, 54484 "5AB 4;O :V;L:VA=>3> 287=0G5==O 7030;L=>3> 25-3V4@>:A82VB0<V=C D /Vitamin D total, 54237 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O V=AC;V=C /Insulin, 54004 "5AB 4;O :V;L:VA=>3> 287=0G5==O A5@45G=>3> B@>?>=V=C ", 25@.2, 200 B5ABV2, 58731 "5AB 4;O :V;L:VA=>3> 287=0G5==O ?@>:0;LF8B>=V=C, 100 HB, 25@.2, 54665 01V@ @5035=BV2 Elecsys 4;O :V;L:VA=>3> 287=0G5==O :>=F5=B@0FVW 7030;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (Total PSA), 48323 01V@ @5035=BV2 Elecsys 4;O O:VA=>3> 287=0G5==O ?>25@E=52>3> 0=B835=C 2V@CAC 35?0B8BC B II (HBsAg II), 48366 01V@ @5035=BV2 Elecsys 4;O O:VA=>3> 287=0G5==O 0=B8BV; 4> 2V@CAC 35?0B8BC ! (Anti-HCV II), 53858 <C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O =B5@;59:V=0-6 (-6) /IL-6, 58236  $ < > H ` d j l 8 һһһpһX/hLnB*CJOJQJaJmH"nHphsH"tH2h$>*B*CJOJQJaJmH"nHphsH"tH/h$B*CJOJQJaJmH"nHphsH"tH0h]jhq>*B*CJOJQJaJnHphtH-h]jhqB*CJOJQJaJnHphtH$h]jhqCJOJQJaJnHtH3h]jhq5B*CJOJQJ\aJnHphtH" $ > l <  (;ؐܐ$d$Ifa$gdohh$7d`7a$gdn- dgd $7d`7a$gdq dgdq $da$gdq8 : < N X l ~   иokcTA&5h hqB*CJOJQJaJmH"nHphsH"tH$h h$CJOJQJaJmH"sH"h h$CJOJQJaJh mH"sH"h$0h]jh$>*B*CJOJQJaJnHphtH0h]jhq>*B*CJOJQJaJnHphtH-h]jhqB*CJOJQJaJnHphtH/h B*CJOJQJaJmH"nHphsH"tH,h$hqCJOJQJaJmH"nHsH"tH/h|B*CJOJQJaJmH"nHphsH"tH   ( 8 : Z ^ 8:Tnα΀hQhhQhhQQQh-h]jhqB*CJOJQJaJnHphtH/h$B*CJOJQJaJmH"nHphsH"tH/h~B*CJOJQJaJmH"nHphsH"tH0h]jhq>*B*CJOJQJaJnHphtH8h$hq>*B*CJOJQJaJmH"nHphsH"tH5h$hqB*CJOJQJaJmH"nHphsH"tH,h hqCJOJQJaJmH"nHsH"tH $&(.ptvx紝eK4-h]jhqB*CJOJQJaJnHphtH3h]jhq5B*CJOJQJ\aJnHphtH8hohhhq>*B*CJOJQJaJmH"nHphsH"tH5hohhhqB*CJOJQJaJmH"nHphsH"tH,h|hqCJOJQJaJmH"nHsH"tH/h|B*CJOJQJaJmH"nHphsH"tH5h$h$B*CJOJQJaJmH"nHphsH"tH/h$B*CJOJQJaJmH nHphsH tHx 4Xjlvx~ $&(,<JRTdͷ{{{{{{{{{{{{{{{{{"hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tH'hohhhohh5OJQJmH"nH"sH"tH"+hohhhohh5OJPJQJmH"nHsH"tH+hohhhohh5OJPJQJmH"nHsH"tH8hohhhq5B*CJOJQJaJmH"nHphsH"tH0hprz|,0:<LDT &(8"R\^'hohhhohh5OJQJmH"nH"sH"tH""hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tHM^lntv&68NPVZ^`hjpv|~(*06F $44<@HJPVf,46LN'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtHMNVXfhx    ( 2 4 D !\!b!d!j!l!r!z!!!!!!!!"""("*":"<"B"P"Z"\"l""""""""""# ##t#|#~############T$'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtHMT$\$^$h$j$l$n$x$z$$$$$$%"%:%D%F%H%f%t%%%&&&&& &$&&&*&,&<&&&&&&&&&&& ''6'8'H'R'T'`'x'z''''''''''''''(خخخخخخخخخخ*hohhhohh5OJQJ\mH nHsH tH'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtHD(((,(6(8(:(>(@(P(((((((((()))p****+"+$+2+4+>+@+B+R++++++,*,2,4,<,>,N,P,R,T,\,^,`,p,,,,,,,,,,,,,f-v--ԮԮԮԮԮԮԮԮԮԮ"hohhhohh5OJQJ\nHtH'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH*hohhhohh5OJQJ\mH nHsH tHD----........ /////////V0^0`0f0h0n0r001111111$141111B2R2222 333333334444444444444L5T5V5\5^5b5d5t5555'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtHM566666666,7:7>7H7J7L7P7\7j7x7z777778888(868@8P88888888899J9\9^9l9|9992:::<:B:D:T:; ;;;;;հ$hohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tH'hohhhohh5OJQJmH"nH"sH"tH"<;l;;;< <"<&<(<.<6<><B<R<<<<== =============">&>*>4>6>D>F>L>R>`>>>>>H?\?^?f?j?p????????ѽ"hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tH'hohhhohh5OJQJmH"nH"sH"tH"+hohhhohh5OJPJQJmH"nHsH"tH/hqB*CJOJQJaJmH"nHphsH"tH:?@@@@ @"@$@(@.@0@@@@@@@@@DDDHDXDDDDDDEEEE E"E$E&E6E'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtHM6EEEEEEEEEEEEEFF F FFzFFFFFFFFFF^GbGtG|G~GGH&HHHHHHHHHHH.IIDITI^I`IpIIIIIIIIIJJJJJJJJJKKKKKKK'hohhhohh5OJQJmH"nH"sH"tH""hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tHMKKKK>LFLJL\L`LrLvL|LLLLLLLLLMMMMMM M0MMMMMMMMMMMMMRNZN\NdNfNpNrNNNNNNOO OOO*O,O.O0O2O4O:OBONOOOOOOOOPP PP&P'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtHM&P(P8PPPPPPPPQQ~QQQQQQQQQQQQBRJRNRVRXRbRdRRRRRRRRRRRRSSS S"S$S(S*S:SLSdSfSvSSSSSSSSSSSSS"T(T*hohhhohh5OJQJ\mH nHsH tH"hohhhohh5OJQJ\nHtH'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tHD(T*TTTTXTdTjT U0U6UU V.V8VVVVVVVVVVnWxWzW|WWWWWWWWWWWWWWWW6X8X:X>XBXVXXXfXhXnXrXXXY|YYYYYZZZ"Z&Z6ZZ*hohhhohh5OJQJ\mH nHsH tH'hohhhohh5OJQJmH"nH"sH"tH""hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tHDZZ$[,[.[2[4[:[>[N[[[[[[[[\\\\\\\\\\],]<]]]Z^j^^^>_H_J_P_R_b___`````$`&`*`,`<`\`j````````axa|aaaȊ(U"hohhhohh5OJQJ\nHtH*hohhhohh5OJQJ\mH"nHsH"tH'hohhhohh5OJQJmH"nH"sH"tH"L!8AB5<=89 @>7G8= 4;O 35=5@0FVW 5;5:B@>EV<VG=8E A83=0;V2 2 V<C=>0=0;V70B>@0E Elecsys, cobas e, 59058 !8AB5<=89 @>7G8= 4;O G8AB:8 45B5:B>@=>3> 1;>:C, Elecsys, cobas e, 58236 >7G8= Elecsys Sys Wash, 61032 >2?0G>: (@50:FV9=0 ?@>1V@:0) 4;O 28:>@8AB0==O 2 A8AB5<0E cobas e 411/Elecsys 2010, 16822 0:V=5G=8: 4;O 28:>@8AB0==O 2 A8AB5<0E cobas e 411/Elecsys 2010, 61032 @>1V@:0 4;O 7@07:V2, 58237 >7G8==8: C=V25@A0;L=89 /Universal Diluent, 54670 01V@ @5035=BV2 Elecsys 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (free PSA), 38183 0;V1@C20;L=89 =01V@ 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (free PSA) 3. =D>@<0FVO ?@> B5E=VG=V, O:VA=V B0 V=HV E0@0:B5@8AB8:8 ?@54<5B0 70:C?V2;V: 73V4=> 7 4>40B:>< ! 2 4> >3>;>H5==O. 4. V;L:VABL B0 <VAF5 ?>AB0G0==O B>20@V2 01> >1AO3 V <VAF5 28:>=0==O @>1VB G8 =040==O ?>A;C3: 4.1.V;L:VABL: !>4  024:201909<5=C20==O48=8FO 28<V@C$0AC20==OV;L:VABL153307"5AB 4;O :V;L:VA=>3> 287=0G5==O 3;N:>78 /Glucose HK Gen.3 (GLUC3)HB800 B5ABV214253231"5AB 4;O :V;L:VA=>3> 287=0G5==O 7030;L=>3> 2<VABC 1V;V@C1V=C, 250 B5ABV2/Bilirubin Total Gen.3HB250 B5ABV248353236"5AB 4;O :V;L:VA=>3> 287=0G5==O ?@O<>3> 1V;V@C1V=C /Bilirubin-Direct (BIL-D2)HB350 B5ABV232453989"5AB 4;O 287=0G5==O 7030;L=>3> 2<VABC 1V;:C /TP2/Total Protein Gen.2 HB300 B5ABV236553590"5AB 4;O :V;L:VA=>3> 287=0G5==O A5G>28=8/ 07>BC A5G>28=8 /(UREA)HB500 B5ABV224653252"5AB 4;O :V;L:VA=>3> 287=0G5==O :@50B8=8=C /Creatinine Jaff Gen.2 (700 tests)HB700 B5ABV217753362"5AB 4;O 287=0G5==O 7030;L=>3> E>;5AB5@8=C /CHOL HiCo Gen.2, cobas c, Int.HB400 B5ABV224853462"5AB 4;O :V;L:VA=>3> 287=0G5==O B@83;VF5@84V2 /Triglycerides (TRIGL)HB250 B5ABV216953393"5AB 4;O :V;L:VA=>3> 287=0G5==O E>;5AB5@8=C-), Gen.4 HB350 B5ABV2121053412"5AB 4;O 287=0G5==O )-E>;5AB5@8= 3 ?>:>;V==O (200 B5ABV2)HB200 B5ABV2201152925"5AB 4;O :V;L:VA=>3> 287=0G5==O 0;0=V=0<V=>B@0=AD5@078 (") /Alanine Aminotransferase acc. to IFCC (ALTL)HB500 B5ABV2241252955"5AB 4;O :V;L:VA=>3> 287=0G5==O 0A?0@B0B0<V=>B@0=AD5@078(!") /Aspartate Aminotransferase acc. to IFCC (ASTL)HB500 B5ABV2241352941"5AB 4;O :V;L:VA=>3> 287=0G5==O 0;LD0-0<V;078 /AMYL2/ alpha-Amylase EPS ver.2HB300 B5ABV2281438502"5AB 4;O :V;L:VA=>3> 287=0G5==O 0;LD0-0<V;078 ?V4H;C=:>2>W 70;>78 /alpha-Amylase EPS Pancreatic (AMY-P)HB200 B5ABV281552929"5AB 4;O :V;L:VA=>3> 287=0G5==O ;C6=>W D>AD0B078, 400 B5ABV2 /Alkaline Phosphatase acc. to IFCC Gen.2 ALP2LHB400 B5ABV281653030"5AB 4;O 287=0G5==O 30<<0-3;CB0<V;B@0=AD5@078 /GGT gamma-Glutamyltransferase ver.2 HB400 B5ABV221738512"5AB 4;O :V;L:VA=>3> 287=0G5==O :0B0;VB8G=>W 0:B82=>ABV :@50B8=:V=078 MB-D@0:FVW CKMB2HB100 B5ABV281838512"5AB 4;O :V;L:VA=>3> 287=0G5==O 0:B82=>ABV :@50B8=:V=078, 200 B5ABV2HB200 B5ABV221953586"5AB 4;O :V;L:VA=>3> 287=0G5==O A5G>2>W :8A;>B8 /UA2/Uric Acid ver.2 HB400 B5ABV282052875"5AB 4;O :V;L:VA=>3> 287=0G5==O :0;LFVN (300 B5ABV2) /Calcium Gen.2 (300 tests)HB300 B5ABV2102154762"5AB 4;O :V;L:VA=>3> 287=0G5==O 70;V70 /IRON2/Iron Gen.2 HB200 B5ABV242253908"5AB 4;O :V;L:VA=>3> 287=0G5==O =5=0A8G5=>W 70;V7>72 O7CNG>W 740B=>ABV A8@>20B:8 :@>2V B0 ?;07<8 /UIBC Unsaturated Iron-Binding CapacityHB100 B5ABV282352883"5AB 4;O :V;L:VA=>3> 287=0G5==O <03=VN, 25@ 2, 250 B5ABV2 / Magnesium Gen.2 250 tests)HB250 B5ABV242452891"5AB 4;O :V;L:VA=>3> 287=0G5==O =5>@30=VG=>3> D>AD0BC /PHOS2/Phosphate (Inorganic) ver.2HB250 B5ABV222553599"5AB 4;O 287=0G5==O :>=F5=B@0FVW 0;L1C<V=C /ALB BCG Gen.2, cobas c, Int.HB300 B5ABV242653719"5AB 4;O :V;L:VA=>3> 287=0G5==O D5@8B8=C (250 B5ABV2) / Tina-quant Ferritin Gen.4 250 tests)HB250 B5ABV242753994"5AB 4;O :V;L:VA=>3> 287=0G5==O B@0=AD5@V=0 /TRSF Tina-quant Transferrin ver.2 HB100 B5ABV212853316"5AB 4;O :V;L:VA=>3> 287=0G5==O 35<>3;>1V=C /Tina-quant Hemoglobin A1c Gen.3 HB150 B5ABV2122947349"5AB 4;O :V;L:VA=>3> 287=0G5==O ?@>4C:BV2 @>7?04C DV1@8=V2 (100 B5ABV2) /Tina-quant D-Dimer Gen.2 (100 tests)HB100 B5ABV213053707"5AB 4;O :V;L:VA=>3> 287=0G5==O !-@50:B82=>3> 1V;:0 (CRP), 4 35=., cobas c 311/501/502, IntegraHB250 B5ABV2123155113"5AB 4;O :V;L:VA=>3> 287=0G5==O @52<0B>W4=>3> D0:B>@C /Rheumatoid Factors II (RF-II)HB100 B5ABV2123237756"5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> AB@5?B>;V78=C  / ASLO" Tina-quant Antistreptolysin OHB150 B5ABV283347869>=B@>;L Precicontrol Clinchem 1 (4x5<;) /Precicontrol Clinchem 1 (4x5ml)=01V@4 E 5 <; 13447869>=B@>;L Precicontrol Clinchem 2 (4x5<;) /Precicontrol Clinchem 2 (4x5ml)=01V@4 E 5 <; 13552869 >7G8= 4;O @5D5@5=B=>3> 5;5:B@>40 /ISE Reference Electrolyte =01V@5 E 300 <; 13658237ISE @>7102;N20G 4;O :V;L:VA=>3> 287=0G5==O =0B@VN, :0;VN, E;>@84C 2 A8@>20BFV, ?;07<V 01> A5GV=01V@5 E 300 <; 13752869ISE AB0=40@B 2=CB@VH=V9 4;O :V;L:VA=>3> 287=0G5==O =0B@VN, :0;VN, E;>@84C 2 A8@>20BFV, ?;07<V 01> A5GV=01V@5 E 600 <; 53858236@><82=89 @>7G8= NaOHD 4;O ?@>1 @5035=BC B0/01> @50:FV9=8E :0<5@ 2 A8AB5<0E Roche/Hitachi cobas cHB58,7 <; 123958237>102:0 4;O 7=865==O ?>25@E=52>3> =0BO3C 2 @50:FV9=>W 20==V 0=0;V70B>@0 cobas c 311HB55,9 <; 164058236@><82=89 @>7G8= Cell wash Solution I/NaOH-D=01V@2 E 1800 <; 441611655<>;V7CNG89 @5035=B, 51 <; /H1CD2 Hemolyzing Reagent Gen.2HB51 <; 14254386"5AB-A8AB5<0 4;O 287=0G5==O B8@5>B@>?=>3> 3>@<>=C 2 35=.HB200 B5ABV2124354413<C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O =572'O70=>3> B8@>:A8=C, gen.IIIHB200 B5ABV244454417<C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> B@89>4BV>=V=C /FT3 Gen.3HB200 B5ABV224554084"5AB-A8AB5<0 4;O 287=0G5==O :0;LF8B>=V=CHB100 B5ABV224658728<C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> B8@5>3;>1C;V=C, 25@ 4 /Anti-Tg Gen.4HB100 B5ABV214758729<C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O 0=B8BV; 4> B8@5>?5@>:A84078, 25@. 3 /Anti-TPO Gen.3HB100 B5ABV284854484"5AB 4;O :V;L:VA=>3> 287=0G5==O 7030;L=>3> 25-3V4@>:A82VB0<V=C D /Vitamin D totalHB100 B5ABV244954237<C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O V=AC;V=C /InsulinHB100 B5ABV225054004"5AB 4;O :V;L:VA=>3> 287=0G5==O A5@45G=>3> B@>?>=V=C ", 25@.2, 200 B5ABV2 HB200 B5ABV225158731"5AB 4;O :V;L:VA=>3> 287=0G5==O ?@>:0;LF8B>=V=C, 100 HB, 25@.2=01V@100 B5ABV21525466501V@ @5035=BV2 Elecsys 4;O :V;L:VA=>3> 287=0G5==O :>=F5=B@0FVW 7030;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (Total PSA)HB100 B5ABV24534832301V@ @5035=BV2 Elecsys 4;O O:VA=>3> 287=0G5==O ?>25@E=52>3> 0=B835=C 2V@CAC 35?0B8BC B II (HBsAg II)HB100 B5ABV212544836601V@ @5035=BV2 Elecsys 4;O O:VA=>3> 287=0G5==O 0=B8BV; 4> 2V@CAC 35?0B8BC ! (Anti-HCV II)=01V@100 B5ABV235553858<C=>B5AB 4;O :V;L:VA=>3> 287=0G5==O =B5@;59:V=0-6 (-6) /IL-6HB100 B5ABV225658236!8AB5<=89 @>7G8= 4;O 35=5@0FVW 5;5:B@>EV<VG=8E A83=0;V2 2 V<C=>0=0;V70B>@0E Elecsys, cobas e=01V@6 E 380 <; 125759058!8AB5<=89 @>7G8= 4;O G8AB:8 45B5:B>@=>3> 1;>:C, Elecsys, cobas e =01V@6 E 380 <; 125858236 >7G8= Elecsys Sys WashHB1 E 500 <; 25961032>2?0G>: (@50:FV9=0 ?@>1V@:0) 4;O 28:>@8AB0==O 2 A8AB5<0E cobas e 411/Elecsys 2010?0:>260 E 60260168220:V=5G=8: 4;O 28:>@8AB0==O 2 A8AB5<0E cobas e 411/Elecsys 2010?0:>230 E 120 46161032@>1V@:0 4;O 7@07:V2 ?0:>25000 HB16258237 >7G8==8: C=V25@A0;L=89 /Universal Diluent=01V@2 E 36 <; 1635467001V@ @5035=BV2 Elecsys 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (free PSA)HB100 B5ABV2164381830;V1@C20;L=89 =01V@ 4;O :V;L:VA=>3> 287=0G5==O 2V;L=>3> ?@>AB0B>A?5F8DVG=>3> 0=B835=C (free PSA)=01V@4 x 1.0 <; 1 4.2. VAF5 ?>AB0G0==O B>20@V2: 46023, <."5@=>?V;L, 2C;. .C?G8=AL:>3>,14 5.13@C=BC20==O: 0:C?V2;O 74V9A=NTBLAO :5@CNG8AL #:07>< @57845=B0 #:@0W=8 2V4 24.02.2022@>:C !64  HYPERLINK "https://s7497428.sendpul.se/sl/MjM2ODg0NjY=/e37244200f07be6a48db794cf0dbd56f384ees4" \t "_blank" @> 22545==O 2>T==>3> AB0=C 2 #:@0W=V B0 ?>AB0=>2>N 01V=5BC V=VAB@V2 #:@0W=8 2V4 28.02.2022 ! 169 5O:V ?8B0==O 74V9A=5==O >1>@>==8E B0 ?C1;VG=8E 70:C?V25;L B>20@V2, @>1VB V ?>A;C3 2 C<>20E 2>T==>3> AB0=C 7V 7<V=0<8, 70B25@465=8<8 ?>AB0=>2>N 01V=5BC V=VAB@V2 #:@0W=8 2V4 24.06.2022 @>:C !723. 6. !B@>: ?>AB0G0==O B>20@V2, =040==O ?>A;C3 01> 28:>=0==O @>1VB: 7 <><5=BC ?V4?8A0==O 4>3>2>@C 4> 7025@H5==O 2V9AL:>2>3> AB0=C. 7. #<>28 >?;0B8: ?;0B0 70 ?>AB02;5=89 ">20@, 74V9A=NTBLAO 0<>2=8:>< 2?@>4>26 30 (B@84FOB8) :0;5=40@=8E 4=V2 7 <><5=BC >B@8<0==O :>6=>W >:@5<>W ?0@BVW ">20@C, =0 ?V4AB02V =0;56=> >D>@<;5=8E ?5@28==8E 4>:C<5=BV2 - 2840B:>2>W =0:;04=>W . 8. GV:C20=0 20@BVABL ?@54<5B0 70:C?V2;V: 1400000,00 3@=. (48= <V;L9>= G>B8@8AB0 B8AOG 3@=. =C;L :>?.), 7 . 9. 5@V>4 CB>G=5==O V=D>@<0FVW ?@> 70:C?V2;N: =0 E- Tender. 10. V=F5289 AB@>: ?>40==O ?@>?>78FV9: =0 E- Tender. 11. 5@5;V: :@8B5@VW2 B0 <5B>48:0 >FV=:8 ?@>?>78FV9 V7 707=0G5==O< ?8B><>W 2038 :@8B5@VW2: 48=8< :@8B5@VT< >FV=:8 T FV=0 (?8B><0 2030 :@8B5@VN  100 %). FV=:0 ?@>?>78FV9 ?@>2>48BLAO 02B><0B8G=> 5;5:B@>==>N A8AB5<>N 70:C?V25;L =0 >A=>2V :@8B5@VN V <5B>48:8 >FV=:8, 707=0G5=8E C FL><C 3>;>H5==V, B0 H;OE>< 70AB>AC20==O 5;5:B@>==>3> 0C:FV>=C. > ?>G0B:C ?@>2545==O 5;5:B@>==>3> 0C:FV>=C 2 5;5:B@>==V9 A8AB5<V 70:C?V25;L 02B><0B8G=> @>7:@820TBLAO V=D>@<0FVO ?@> FV=C B0 ?5@5;V: CAVE FV= ?@>?>78FV9, @>7<VI5=89 C ?>@O4:C 2V4 =09=86G>W 4> =0928I>W FV=8 157 707=0G5==O =09<5=C20=L B0 V=D>@<0FVW ?@> CG0A=8:V2. V4 G0A ?@>2545==O 5;5:B@>==>3> 0C:FV>=C 2 5;5:B@>==V9 A8AB5<V 70:C?V25;L 2V4>1@060NBLAO 7=0G5==O FV=8 ?@>?>78FVW CG0A=8:0. > >FV=:8 ?@>?>78FV9 ?@89<0TBLAO AC<0, I> AB0=>28BL 7030;L=C 20@BVABL ?@>?>78FVW :>6=>3> >:@5<>3> CG0A=8:0, @>7@0E>20=0 7 C@0EC20==O< 28<>3 I>4> B5E=VG=8E, O:VA=8E B0 :V;L:VA=8E E0@0:B5@8AB8: ?@54<5BC 70:C?V2;V, 287=0G5=8E F8< >3>;>H5==O<, 2 B><C G8A;V 7 C@0EC20==O< 2:;NG5==O 4> FV=8 ?>40B:C =0 4>40=C 20@BVABL (), O:I> CG0A=8: T ?;0B=8:>< , V=H8E ?>40B:V2 B0 71>@V2, I> ?5@5410G5=V G8==8< 70:>=>402AB2><, B0 <0NBL 1CB8 2:;NG5=V B0:8< CG0A=8:>< 4> 20@B>ABV B>20@C. 12. >7<V@ B0 C<>28 =040==O 70157?5G5==O ?@>?>78FV9 CG0A=8:V2: =5 ?5@5410G5=>. 13. >7<V@ B0 C<>28 =040==O 70157?5G5==O 28:>=0==O 4>3>2>@C ?@> 70:C?V2;N: =5 ?5@5410G5=>. 14. >7<V@ <V=V<0;L=>3> :@>:C ?>=865==O FV=8 ?V4 G0A 5;5:B@>==>3> 0C:FV>=C: 0,5%. 15. =H0 V=D>@<0FVO: 15.1.#G0A=8: ?>28=5= 4>40B8 4> ?@>?>78FVW 4>:C<5=B8 73V4=> >40B:C 1. 15.2. >:C<5=B8, 283>B>2;5=V 157?>A5@54=L> #G0A=8:><, I> ?>40NBLAO C A:;04V ?@>?>78FVW, ?>28==V 1CB8 2V4A:0=>20=V 7 >@83V=0;V2 4>:C<5=BV2, B0 <VAB8B8 B0:V @5:2V78B8: 40B0, 28EV4=89 =><5@, ?@V728I5, V<'O B0 ?V4?8A C?>2=>2065=>W >A>18 #G0A=8:0. >?VW V=H8E 4>:C<5=BV2, I> ?>40NBLAO C A:;04V ?@>?>78FVW, <0NBL 1CB8 70A2V4G5=V C 2AB0=>2;5=><C 70:>=>402AB2>< ?>@O4:C. 15.3. >40B:8: >40B>: !1.5@5;V: 4>:C<5=BV2, O:V 28<030NBLAO 4;O ?V4B25@465==O 2V4?>2V4=>ABV ?@>?>78FVW CG0A=8:0 28<>30< 70<>2=8:0 >40B>: !2. =D>@<0FVO ?@> =5>1EV4=V B5E=VG=V, O:VA=V B0 :V;L:VA=V E0@0:B5@8AB8:8 ?@54<5B0 70:C?V2;V >40B>: ! 3  8AB-73>40 =0 >1@>1:C ?5@A>=0;L=8E 40=8E >40B>: ! 4  $>@<0 &V=>20 ?@>?>78FVO. >40B>: ! 5  @>T:B 4>3>2>@C ?@> 70:C?V2;N. (6:DFHLXftv|~ $2<LŒ̌܌FXZhx.68>@P ح/hqB*CJOJQJaJmH"nHphsH"tH,h~5CJOJQJ\aJmH"nHsH"tH'hohhhohh5OJQJmH"nH"sH"tH"*hohhhohh5OJQJ\mH"nHsH"tH"hohhhohh5OJQJ\nHtH4ڏ܏2<֐ؐ˴o˴W?(,hNhNCJOJQJaJmH"nHsH"tH/hNB*CJOJQJaJmH"nHphsH"tH/hqB*CJOJQJaJmH"nHphsH"tH2hN>*B*CJOJQJaJmH"nHphsH"tH$h]jhqCJOJQJaJnHtH/hohhB*CJOJQJaJmH"nHphsH"tH-h]jhqB*CJOJQJaJnHphtH0h]jhq>*B*CJOJQJaJnHphtH5hohhhqB*CJOJQJaJmH"nHphsH"tHؐܐ\^bn& ֓ؓܓLNR^ $0LNT` ".؞ڞ$hohhhohhCJOJQJaJnHtH'hohhhohhCJOJQJ\aJnHtH$hohhhohhCJOJQJaJnH"tH"/hohhhohhCJOJQJ\aJmH"nHsH"tHD4H\$d$Ifa$gdohh\^bn/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;n$d$Ifa$gdohhd$Ifgdohh&/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;&$d$Ifa$gdohhd$Ifgdohh /$d$Ifa$gdohhkd $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;Г֓$d$Ifa$gdohhd$Ifgdohh֓ؓܓ/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;tz$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;*0FL$d$Ifa$gdohhd$IfgdohhLNR^/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;^$d$Ifa$gdohhd$Ifgdohh $0/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;0Ɩ̖$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd#$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd($$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;*0FL$d$Ifa$gdohhd$IfgdohhLNT`/$d$Ifa$gdohhkd- $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;`ژ$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd2 $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$d$Ifa$gdohhd$Ifgdohh /$d$Ifa$gdohhkd7 $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$d$Ifa$gdohhd$Ifgdohh"./$d$Ifa$gdohhkd< $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;.ʛЛ$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkdA $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;М֜$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkdF$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ܝ$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkdK$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;Ԟ؞$d$Ifa$gdohhd$Ifgdohh؞ڞ/$d$Ifa$gdohhkdP$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ڞŸΟxz8:@L$̢ȥʥХܥ|~PRXd$&,846<H46<H( .$hohhhohhCJOJQJaJnHtH'hohhhohhCJOJQJ\aJnHtH$hohhhohhCJOJQJaJnH"tH"/hohhhohhCJOJQJ\aJmH"nHsH"tHC$d$Ifa$gdohhd$IfgdohhŸΟ/$d$Ifa$gdohhkdU$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ΟX^tx$d$Ifa$gdohhd$Ifgdohhxz/$d$Ifa$gdohhkdZ$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;48$d$Ifa$gdohhd$Ifgdohh8:@L/$d$Ifa$gdohhkd_$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;L $d$Ifa$gdohhd$Ifgdohh$/$d$Ifa$gdohhkdd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$$d$Ifa$gdohhd$Ifgdohh̢/$d$Ifa$gdohhkdi$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;̢$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkdn$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;¤Ȥޤ$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkds$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ĥȥ$d$Ifa$gdohhd$IfgdohhȥʥХܥ/$d$Ifa$gdohhkdx$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ܥnt$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd}$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;\bx|$d$Ifa$gdohhd$Ifgdohh|~/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;06LP$d$Ifa$gdohhd$IfgdohhPRXd/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;d$$d$Ifa$gdohhd$Ifgdohh$&,8/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;804$d$Ifa$gdohhd$Ifgdohh46<H/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;H.4$d$Ifa$gdohhd$Ifgdohh46<H/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;H$d$Ifa$gdohhd$Ifgdohh(/$d$Ifa$gdohhkd$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;( $d$Ifa$gdohhd$Ifgdohh /$d$Ifa$gdohhkd $$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;.hl֭حޭ48~Z\bnTV\h^`frTV\h.06BTVbƳȳγڳ Rjlr~&е$hohhhohhCJOJQJaJnH"tH"/hohhhohhCJOJQJ\aJmH"nHsH"tH$hohhhohhCJOJQJaJnHtH'hohhhohhCJOJQJ\aJnHtH/hohhhohhCJOJQJ\aJmH nHsH tH:ҭ֭$d$Ifa$gdohhd$Ifgdohh֭حޭ/$d$Ifa$gdohhkd!$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;~$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd"$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;2>VZ$d$Ifa$gdohhd$IfgdohhZ\bn/$d$Ifa$gdohhkd#$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;n,8PT$d$Ifa$gdohhd$IfgdohhTV\h/$d$Ifa$gdohhkd$$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;h6BZ^$d$Ifa$gdohhd$Ifgdohh^`fr/$d$Ifa$gdohhkd%$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;r6<NT$d$Ifa$gdohhd$IfgdohhTV\h/$d$Ifa$gdohhkd&$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;h(.$d$Ifa$gdohhd$Ifgdohh.06B/$d$Ifa$gdohhkd'$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;B³Ƴ$d$Ifa$gdohhd$IfgdohhƳȳγڳ/$d$Ifa$gdohhkd($$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ڳRXfj$d$Ifa$gdohhd$Ifgdohhjlr~/$d$Ifa$gdohhkd)$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;~ $d$Ifa$gdohhd$Ifgdohh&/$d$Ifa$gdohhkd*$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;&̵е$d$Ifa$gdohhd$Ifgdohhеҵص/$d$Ifa$gdohhkd+$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;еҵص , ܸ޸ȹVX^j "(4ػڻ XZ`lT®®®®®®®®®®®®®®®®®'hohhhohhCJOJQJ\aJnHtH$hohhhohhCJOJQJaJnH"tH"/hohhhohhCJOJQJ\aJmH"nHsH"tH$hohhhohhCJOJQJaJnHtHDrx$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd,$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$d$Ifa$gdohhd$Ifgdohh ,/$d$Ifa$gdohhkd-$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;,ַܷ$d$Ifa$gdohhd$Ifgdohh /$d$Ifa$gdohhkd.$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt; ¸ظܸ$d$Ifa$gdohhd$Ifgdohhܸ޸/$d$Ifa$gdohhkd/$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$d$Ifa$gdohhd$Ifgdohhȹ/$d$Ifa$gdohhkd0$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ȹ6<RV$d$Ifa$gdohhd$IfgdohhVX^j/$d$Ifa$gdohhkd1$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;j $d$Ifa$gdohhd$Ifgdohh "(4/$d$Ifa$gdohhkd2$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;4Իػ$d$Ifa$gdohhd$Ifgdohhػڻ/$d$Ifa$gdohhkd3$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;ּܼ$d$Ifa$gdohhd$Ifgdohh /$d$Ifa$gdohhkd5$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt; ֽܽ$d$Ifa$gdohhd$Ifgdohh /$d$Ifa$gdohhkd 6$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt; ¾ξ$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd7$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;~$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd8$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;lx$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd9$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;.:RX$d$Ifa$gdohhd$IfgdohhXZ`l/$d$Ifa$gdohhkd:$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;l$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd";$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;z$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd'<$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;0<PT$d$Ifa$gdohhd$IfgdohhTV\h/$d$Ifa$gdohhkd,=$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;TV\hDFLXBDJVBDZ^h~®®®®~fKK5hohhhqB*CJOJQJaJmH"nHphsH"tH/hqB*CJOJQJaJmH"nHphsH"tH/hBB*CJOJQJaJmH"nHphsH"tH/hNB*CJOJQJaJmH"nHphsH"tH'hohhhohhCJOJQJ\aJnHtH$hohhhohhCJOJQJaJnH"tH"/hohhhohhCJOJQJ\aJmH"nHsH"tH$hohhhohhCJOJQJaJnHtHh$d$Ifa$gdohhd$Ifgdohh/$d$Ifa$gdohhkd1>$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;*@D$d$Ifa$gdohhd$IfgdohhDFLX/$d$Ifa$gdohhkd6?$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;X"(>B$d$Ifa$gdohhd$IfgdohhBDJV/$d$Ifa$gdohhkd;@$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;V&>B$d$Ifa$gdohhd$IfgdohhBD/" $da$gdqkd@A$$IfֈrcL"%FeF?FBB tL&62 24 4Bap<yt;$&ϷkTATkTk-k&hCJOJQJaJmH"nH"sH"tH"$hszhszCJOJPJQJmH"sH"-jhszhszCJOJPJQJUmH"sH",hszhszCJOJQJaJmH"nH"sH"tH"8hszhsz>*B*CJOJQJaJmH"nHphsH"tH/hszB*CJOJQJaJmH"nHphsH"tH/hqB*CJOJQJaJmH"nHphsH"tH/h2B*CJOJQJaJmH"nHphsH"tH/hohhB*CJOJQJaJmH"nHphsH"tH $. թqWq@%5h hqB*CJOJQJaJmH"nHphsH"tH,h h CJOJQJaJmH"nHsH"tH2hN>*B*CJOJQJaJmH"nHphsH"tH8hszhq>*B*CJOJQJaJmH"nHphsH"tH5hszhqB*CJOJQJaJmH"nHphsH"tH/hszB*CJOJQJaJmH"nHphsH"tH&hBZCJOJQJaJmH"nH"sH"tH",hszhszCJOJQJaJmH"nH"sH"tH"&h(SCJOJQJaJmH"nH"sH"tH"  b86b 0 $]a$gdB $da$gdB$d@&a$gdB$7d`7a$gdqgd[  $<@HLѹiR;";0h]jhq>*B*CJOJQJaJnHphtH-h]jhqB*CJOJQJaJnHphtH,hBhBCJOJQJaJmH"nHsH"tH8hszhq>*B*CJOJQJaJmH"nHphsH"tH5hszhqB*CJOJQJaJmH"nHphsH"tH/hszB*CJOJQJaJmH"nHphsH"tH/hBB*CJOJQJaJmH"nHphsH"tH/h7B*CJOJQJaJmH"nHphsH"tH,h hqCJOJQJaJmH"nHsH"tH LZpʰ|_K3/hszB*CJOJQJaJmH"nHphsH"tH'h&)hq5CJOJQJaJnHtH8h&)hq5B*CJOJQJaJmH"nHphsH"tH2ha5B*CJOJQJaJmH"nHphsH"tH2h{5B*CJOJQJaJmH"nHphsH"tH2hO5B*CJOJQJaJmH"nHphsH"tH0h&)hq5B*CJOJQJaJnHphtH8hOhO5B*CJOJQJaJmH"nHphsH"tH @BDJLP\`bfj跟p]E*5h:qh:qB*CJOJQJaJmH"nHphsH"tH/hszB*CJOJQJaJmH"nHphsH"tH$h]jhqCJOJQJaJnHtH-h:qh:qB*CJOJQJaJnHphtH/h:qB*CJOJQJaJmH nHphsH tH/h:qB*CJOJQJaJmH"nHphsH"tH/hqB*CJOJQJaJmH"nHphsH"tH0h]jhq>*B*CJOJQJaJnHphtH-h]jhqB*CJOJQJaJnHphtH(268:<@繢w^Fw^/h2B*CJOJQJaJmH"nHphsH"tH0h]jhq>*B*CJOJQJaJnHphtH/hszB*CJOJQJaJmH"nHphsH"tH$h]jhqCJOJQJaJnHtH-h]jhqB*CJOJQJaJnHphtH-h]jh:qB*CJOJQJaJnHphtH-h:qh:qB*CJOJQJaJnHphtH/h:qB*CJOJQJaJmH nHphsH tHj$(2468:>\`bxйСЈuСЈ^uСЈuFF/h;B*CJOJQJaJmH"nHphsH"tH-h:qh:qB*CJOJQJaJnHphtH$h]jhqCJOJQJaJnHtH0h]jhq>*B*CJOJQJaJnHphtH/hszB*CJOJQJaJmH"nHphsH"tH,hJhqCJOJQJaJmH"nHsH"tH-h]jhqB*CJOJQJaJnHphtH/hqB*CJOJQJaJmH"nHphsH"tH  " ѺѺѺѺѺpQѺ<h;h;B*CJOJPJQJ\aJmH"nHphsH"tH<h;hBB*CJOJPJQJ\aJmH"nHphsH"tH$h]jhqCJOJQJaJnHtH/hszB*CJOJQJaJmH"nHphsH"tH-h]jhqB*CJOJQJaJnHphtH/h;B*CJOJQJaJmH"nHphsH"tH,h;hqCJOJQJaJmH"nHsH"tH.0DFXZ|~м楍uu]J6&h:uCJOJQJaJmH"nHsH"tH$h]jhqCJOJQJaJnHtH/hqB*CJOJQJaJmH"nHphsH"tH/heB*CJOJQJaJmH"nHphsH"tH/hBB*CJOJQJaJmH"nHphsH"tH-h]jhqB*CJOJQJaJnHphtH&hBCJOJQJaJmH"nHsH"tH+hBB*CJOJPJQJaJmH"phsH"1hBhBB*CJOJPJQJaJmH"phsH"gdxdd@&[$\$gdxm$ dgdqh4[hxmH"sH"h4[hx5PJ\mH"sH"hx5PJ\mH"sH",h]jhqCJOJQJaJmH"nHsH"tH<P1h:pq. A!"#$n% Dp$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;$$If!vh#v#ve#v?#v#v-#vr:V  tL&655e5?55/ 2 244Bap<yt;^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH"nH"sH"tH"T`T q1KG=K9 d CJOJQJ_HaJmHsHtH h@"h q 03>;>2>: 2ddd@&[$\$5CJ$OJPJQJ\aJ$tHBA B A=>2=>9 H@8DB 0170F0Xi@X 1KG=0O B01;8F04 l4a .k . 5B A?8A:0 @@ qList Paragraph ^:U`: q 8?5@AAK;:0 >*B*phD/D qA=>2=>9 H@8DB 0170F01Zo!Z q03>;>2>: 2 =0:"5CJ$PJ\_HaJ$mHsHtH\o2\ q57 8=B5@20;01$CJOJQJ^J_HaJmHsHtH ,W`A, FB!B@>3895\"Q" xrvts0PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VCWNIA!ޝ}7/݉%BR7Hw9!p<Ǥፉ.EB\ /T*Y>,cy'$gC."Vso+C1OǓt}8>V3mBb%DWs'O''Gw ~lh;UM!DzŬ;C K^ysJJ1KRμ)~.ک/ Y\n9?[]67)qnpJOF$ w;fCLL&׸m%]V%z-{ v8Ҩm-.xo(-ms~ۜ|s>Ͼ%O04h=یщ!eƌ\f :C*OiIA 64HpUa7 UO3 d:(fA@٣>N"Hhp&hA38 )SUUR'V5&HM.6xpyn,ބ!h^^Z4~0#w,,& g"Ic힍Q)˕C6%^+Hk!$A*#.D)irdq8Y^}q~C>Np%uJx?+al|zf[Ux5b>c!:M (MkIVEpYPҍN2$ÿ -.h۴"P6T{T 6]u̒VhVnR+n;)ȔbL X6Y`+qB]( 0H1$6_[s)k8Tm Aa?R d ڒɾ0{eRF& Ī't\{BHuM6`pGϽO+!XoN'^[crh2*tW<{1U+l_QSncX<)Q(wJH ٯ#zCm>nhf6t}M&ʺ6ײ'\gkNS:;\qN-S;kǺ"{DailL`̗/޿ ^o#I&%0]SPV!] PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!^}-theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] X 8  x^NT$(-5;?6EK&P(TZ(ؐڞ.еT L13456789:;<=>?@ABCDqrs\n&֓L^0L`.؞Οx8L$̢ȥܥ|Pd$84H4H( ֭ZnTh^rTh.BƳڳj~&е, ܸȹVj 4ػ XlThDXBVB2tuvwxyz{|}~KLCLXX8@0(  B S  ?#$-0=>JKSTZ[]^epw} !"&)49DENQX_oqtx ACUVXy}CJNQ OTU\]`9=>AEJNQz J`hopGLMTY\   ' ( + - / 5 8 \ u { , 9 $ % ( ` p   _ h j s u x       ! ( - V a h l m r s ~  *./47<=@HM IVaefkl| OXYdp{QV*.8DQS[e5BHKq}!#&+/47 IX^`GLho<MNUW\ (2PU\ccw r{|"#& @MO\&.56FGJLN "otu|";AFGZ[^H L M Q R U &!6!a!l!m!q!r!y!z!!!!!!!!!!%"."0"9";">"|""""""""""""""""""#'#.#2#3#8#9#D#E#H##############$$$$$c$h$y$$$$$$$$%%'%+%,%1%2%B%U%a%b%j%v%%%%%%%%%%%%&&&*&6&A&''R'W'X'_'`'e'''''' (((!(+(](j(((((((()))7)C)K)T){))))))))))))))))))))I*P*S*X*`*i*****++$+&+E+L+++++++ ,,.,5,l,p,,,,,-----"-\-c-e-j-{------------..".).k.t.u.|.......)/=/H/L/V/`/e/m/o/u/y/}//////////////////////00 0 0000000"0F0R0S0Z0[0a0b0k0l0u00000000000000000011 1 111#1$1-1.131:1<1A1G1]1h1i1s1|1111111111111111111122 22%20212;2<2D2L2T2]2_2d2j222222222222222222222333"3&3)3+3-32383N3Y3Z3d3e3r3t333333333333334 44'4-4345474<4B4Y4d4e4o4p44444444444444444445555/505355575D5F5K5Q5h5s5t5~555555555555555566 6 666'6062676=6S6^6_6i6j6p6q6z666666666666666666677$7&7+717G7R7S7]7^7j7k7u7v77777777777777777777788"8#8-8.85868=8C8G8H8L8T8V8[8a8w88888888888888888888899 9999!979B9C9M9O9Z9[9k9l9u9v9999999999999999999999: :::":':):+:0:6:L:W:X:b:c:p::::::::::::::::::::;; ;";-;.;8;9;A;G;M;Q;[;\;d;o;t;v;x;};;;;;;;;;;;;;;;;<<<<<&<(<2<3<=<I<K<P<V<m<x<y<<<<<<<<<<<<<<<<<<<<<== =="=3=8=I=P=Q=S=X=^=u===================>>>>)>*>:>=>?>D>J>`>l>m>u>>>>>>>>>>>>>>>? ?#?)?.?:?;?D?J?S?T?_?a?f????????????????????? @@@#@$@.@/@5@7@<@H@Q@S@Y@Z@]@^@b@c@h@@@@@@@@@@@@@@@@@@@AAAA'A1A2A7A8ACADAIAPARAiArAsAyAAAAAAAAAAAB"B@BBBGBMB[BdBiBtBuBBBBBBBBBBBBBBBBBBBBCCCC,C6C7CCCDCFCKCQC^CgClCwCxCCCCCCCCCCCCCCCCCCCCC DDD&D(D-D3DIDTDUD_D`DjDDDDDDDDDDDDDDDDDDDDDDDEEEE(E1E@EFEHEJEOEUEkEvEwEEEEEEEEEEEEEEEEEEEEEEEF FF(F-F3F5F:F@FMFRFSF\F]FdFiFqFrF|F}FFFFFFFFFFFFFFFFFFFFFG GGG G)G.G3G9GFGOGTG_G`GjGGGGGGGGGGGGGGGGGGGGGGHH&H'H-HMHTHVH[H_HdH~HHHHHHHHHHHHHHHHHHHHHHI)I/I;IGILISIZI|IIIIIIIIIIIIIIIIIIIJJ JJJJ&J'J/J0JDJOJSJYJ[J`JfJsJJJJJJJJJJJJJJJJK(K*KTETNTRTZT\TaThTnTrTwTxTTTTTTTTTTTTTTTTTTTTTTTU UUUU'U(U-U.U7U8U>=>?>I>J>N>P>>>>> ? ???e?f?v?x?????????@@/@3@g@h@x@z@@@@@PARA`AbAAAAAAAAB@BBBLBMBRBTBeBhBBBBBBBBBCC CCCCDCFCPCQCUCWCCCCCCC&D(D2D3D7D9DEDHDDDDDDDDDDDDD1E3EHEJETEUEYE[EEEEEEEEEEE3F5F?F@FDFFFQFRFFFFFFFGG-G.G8G9G=G?GGGGGGGGGHHHH9HEHcHdHuHwHHHHHIIsIuIIIIIIIIIIIIIYJ[JeJfJjJlJJJJJJ?KJKKMLMMMNNNNN77778T8n8889.999):C::::;v;;;;I<d<<<Q=l====>W>>>?#?a????c@@@@PAiAAAAB@B[BBBCCDC^CCC&D@DDDDDHEbEEE3FMFFF)GFGGGGH_HHII`IIYJsJJJUU8WDW`XXX }\wm +kK$'% #@XUNi\`f캡m6bhrM+NpVd4osh/wyNXp |{HH567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph6..^J^J^J^J^J^J^J^J^`^J.^`^J.pp^p`^J.@ @ ^@ `^J.^`^J.^`^J.^`^J.^`^J.PP^P`^J.H567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph7..^J^J^J^J^J^J^J^JH567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph4..^J^J^J^J^J^J^J^JH567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph6.3..^J^J^J^J^J^J^J^JH567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph6.4..^J^J^J^J^J^J^J^JH567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph2..H567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph..^J^J^J^J^J^J^JH567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph6.2..^J^J^J^J^J^J^J^J  ^` o(. ^` 5B*o(ph..0^`0o(...0^`0o(.... 8^8`o( ..... 8^8`o( ...... `^``o(....... `^``o(........ ^`o(.........H567:>*@B*CJEHOJPJQJRHdS*Y(\]^JaJph8..^J^J^J^J^J^J^J^J m M+Np #@ } 4os i\` m6b K$' p |{ h/wy   ^K)^Kk83";(,-;');(,-sz4/?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'(*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefhijklmnpqrstuv{Root Entry FyW)}Data EB1Table)zWordDocument> SummaryInformation(gDocumentSummaryInformation8oCompObjr  F Microsoft Word 97-2003 MSWordDocWord.Document.89q